Moreover, VWF release can be triggered at the sites of vascular injury or by desmopressin (DDAVP), which is used as a treatment for mild hemophilia A and von Willebrand disease [52,57], which is the most prevalent congenital bleeding disorder that arises from deficiencies in quantity or quality of von Willebrand factor (VWF). This evidence concerns the gene VWF and Von Willebrand disease.